Purpose of Review The purpose of this review is to summarize the available evidence-based HIV prevention interventions tailored for transgender people. Recent Findings A limited number of evidence-based HIV prevention interventions have been tested with transgender populations. Most existing interventions target behavior change among transgender women, with only one HIV prevention program evaluated for transgender men. Studies addressing biomedical interventions for transgender women are ongoing. Few interventions address social and structural barriers to HIV prevention, such as stigma, discrimination, and poverty. Summary Evidence-based multi-level interventions that address the structural, biomedical, and behavioral risks for HIV among transgender populations, including transgender men, are needed to address disparities in HIV prevalence. Future research should address not only pre-exposure prophylaxis uptake and condom use but also structural barriers that limit access to these prevention strategies.
Introduction
The term "transgender" describes a diverse population whose gender identity differs from the sex they were assigned at birth [1] . The sex assigned at birth is typically based on the appearance of external genitalia and recorded on the birth certificate. Gender has been conceptualized in a variety of ways across cultures, regions, and over time [2••] . This review will focus on the published, peer-reviewed HIV literature in which the term "transgender women" refers to people who were assigned male at birth and have a feminine or female gender identity. "Transgender men" refers to people assigned female at birth who have a masculine or male gender identity. While studies of transgender women and men sometimes include people who identify outside the male-female binary, there are very limited HIV data disaggregated for this population; therefore, this review focuses on transgender women and men.
The most recent global data synthesis estimates that 25 million people around the world are transgender [3] . In the USA, where more than 30 states have begun collecting data on gender identity, 0.6% of the population (approximately 1.4 million people) are estimated to be transgender [4] . Scientific inquiry into the health of transgender people has increased exponentially over the last 5 years with a significant This article is part of the Topical Collection on The Science of Prevention * Tonia Poteat tpoteat@jhu.edu
Mannat Malik mmalik7@jhu.edu focus on HIV [5] . At the same time, transgender individuals have become increasingly visible as leaders of transgender health research and destigmatizing approaches to research and clinical practice [6, 7] . The majority of HIV research among transgender people has been with transgender women [8] . Across 15 countries where data were available, transgender women had an estimated HIV prevalence of 19%-a 49-fold increased odds of HIV compared with the general population of reproductive age adults [9] . Additionally, transgender women sex workers were more likely to have HIV than cisgender (non-transgender) female or male sex workers [10] . In most countries, however, seroprevalence data remain unavailable [11] . HIV vulnerability is not distributed evenly across transgender populations. Within the USA, African-American and Latina transgender women bear the heaviest burden [8, 12] . Incidence rates among transgender women of color are high [8] ; and testing data suggest that infection often occurs early, during adolescence [6] . The few existing HIV studies among transgender men have been limited by very small sample sizes [8] . The largest study, based on US Centers for Disease Control (US CDC) data, found 0.5% positivity among testing events known to be among transgender men, higher than the 0.3% national HIV prevalence [12] .
HIV Vulnerabilities Sexual Risk
Multiple studies from around the world have described elevated rates of sexual risk behavior among transgender women. Transgender women who have sex with cisgender (nontransgender) men are more likely than men who have sex with men (MSM) to assume a receptive role during anal intercourse, less likely to use a condom, and have a higher number of sexual partners [13] [14] [15] . Emerging evidence suggests that transgender women have a limited pool of cisgender male partners and those men have elevated HIV risk [16, 17] . We were unable to identify studies of HIV risk among transgender women who partner with transgender men or other women (cisgender or transgender).
Findings from studies of transgender men are heterogeneous, and almost entirely limited to Canada and the USA. In a recent review, estimates of recent condomless vaginal or anal intercourse ranged from 7 to 69% [18] . The inclusion in many studies of transgender men regardless of the sex of their partners contributes to this variability, as most of their sexual partners are cisgender women [19] . Within the sub-group of transgender men sexually active with cisgender men, approximately one third indicated past-year HIV sexual risk in a Canadian study [20] . While little is known about the characteristics of male sexual partners of transgender men in most settings, one US-based study found that the majority also had sex with other cisgender men [21] . Condomless vaginal intercourse appears more frequent than condomless anal intercourse among transgender men [19, 22] . While this may contribute to lower HIV risk, transgender men using testosterone therapy may experience vaginal tissue changes (similar to menopausal cisgender women [23] ) that may increase susceptibility to HIV infection [18] .
Injection Risk
The literature is sparse on transgender people and HIV risk through needle sharing. Exposure to contaminated needles and other paraphernalia may occur during injection of recreational drugs, hormones, or loose soft tissue fillers, such as silicone. Despite significant health risks [24] [25] [26] [27] , soft tissue fillers are commonly injected in the face, breast, and hips and/or buttocks of transgender women to feminize the contour of the face and body [28] . High rates of substance use have been reported in studies of both transgender women and transgender men [29, 30] . In one study, transgender women reporting substance use of any nature were more likely to report needle use to inject drugs, injecting silicone, and sharing needles [29] . Injection drug use has been associated with testing positive for HIV among transgender women [12] . In settings where needles and syringes are readily available via pharmacies and exchange programs, very little needle sharing has been identified [31] . More research is needed to characterize injection and needle sharing practices among transgender people.
Syndemic Risk
Syndemic theory posits that a concentration of negative psychosocial factors interact to increase vulnerability to preventable diseases [32] . Psychosocial syndemic drivers of HIV have been described for multiple populations [33] . These drivers have included stigma, substance use, poor mental health, and exposure to abuse and/or violence. A limited number of studies have corroborated these factors as syndemic drivers of HIV among transgender people [8] . This approach to understanding HIV risk begins to move beyond the individual behavioral-level risk to examine other factors that may be driving HIV disparities for transgender people.
Multi-level Risk
HIV vulnerability is often driven by risks at multiple socioecological levels ranging from structural (laws and policies that create barriers to health care) to network (high-risk sexual partners) to proximal factors (condomless anal intercourse) [34, 35•] . Derived from empirical data with transgender women of color, the Gender Affirmation Framework models how the social contexts of racism, sexism, and transphobia intersect to produce unique circumstances that lead to elevated HIV risk in this population [36] . In short, stigma and discrimination reduce access to employment and health care as well as social, legal, and medical gender affirmation [5] . Under these circumstances, sex work is often the only option available for income [35•] . At the same time, antitransgender stigma also increases the felt need for gender affirmation. Both social oppression and psychological distress produced under these circumstances increase engagement in high-risk contexts such as exchange sex, sex to obtain gender affirmation, and illicit injections of hormones or silicone. Research with transgender men who have sex with men indicates that stigma, syndemic conditions, and gender affirmation may also play important roles in their sexual risk behavior [37] .
HIV Prevention Interventions
Few evidence-based HIV prevention interventions have been developed for and tested among transgender people [38••, 39] ; and only one intervention from the US Centers for Disease Control compendium of evidence-based prevention interventions, SISTA, has been formally adapted for transgender women (T-SISTA) [40] . Table 1 provides the results of a scoping review of evidence-based transgender-specific HIV prevention interventions, organized by intervention approaches: (1) behavioral: interventions that primarily employ individual behavior change approaches to target knowledge, attitudes, and HIV risk behaviors; (2) biomedical: interventions that promote use of biomedical HIV prevention and care methods such as pre-exposure prophylaxis (PrEP) as well as engagement, retention, and adherence to HIV treatment (i.e., treatment as prevention or TasP); and (3) structural: interventions that address social and institutional drivers of HIV vulnerability (e.g., socioeconomic hardship, medical distrust, desire for gender affirmation, discriminatory laws and policies). Table 2 describes transgender-specific HIV prevention interventions currently under study.
Behavioral Interventions
Most transgender-specific HIV prevention interventions for which outcomes data are available target transgender women and are behaviorally focused. These interventions entail a time-limited series of small group sessions that combine didactic and participatory learning (e.g., role playing). The curricula provide education on topics like HIV transmission, condom and lubricant use, condom negotiation, the importance of regular HIV testing, and HIV treatment. Studies of these interventions have focused on outcomes such as number of sex partners, consistency of condom and lubricant use, and knowledge about HIV risk and safer sex practices. Only two studies of behavioral interventions enrolled both transgender women and men, and one focused on transgender men who have sex with men (TMSM). Prioritization of transgender women for HIV prevention is consistent with the heavy burden of HIV in this population and the focus on individual risk behavior is consistent with the high estimated per-act relative risk of acquiring HIV during receptive anal intercourse compared with vaginal intercourse [41, 42] . However, the limited attention to TMSM who may engage in receptive anal intercourse as well as the relatively limited attention to distal factors that drive HIV risk behavior represents an important gap in HIV prevention research.
While outcome measures for most behavioral interventions focused on individual HIV risk behaviors, several interventions also addressed psychosocial factors. For example, some interventions included small group sessions on transgender pride, skill building (e.g., how to access medical care, employment, and housing), communication and respect [39] , as well as sessions on substance use [43, 44] , social support [44, 45] , and personal growth [44] . A few interventions also facilitated referral to social services [43, 45, 46] , including substance abuse treatment [43] , and met practical needs such as showers or clothing [43] . However, these aspects of the intervention were often not specifically evaluated. When psychosocial factors were evaluated, they seldom resulted in significant improvements [39] . The short-term and individual nature of these behavioral interventions may have limited their ability to meaningfully address more distal psychosocial drivers of HIV. Table 2 points to a shift in interventional focus from purely behavioral to combination behavioral and biomedical approaches, with the behavioral component targeting outcomes like retention in HIV care or prevention services and treatment adherence.
Biomedical Interventions
PrEP has emerged as a potentially powerful biomedical prevention strategy, and is currently recommended by the World Health Organization for all individuals at substantial risk for HIV [47••] . The seminal study of oral tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) for PrEP, the iPrEx trial, was designed to assess PrEP efficacy among men who have sex with men but did not exclude transgender women [48] . A sub-analysis of data on transgender women (n = 339) in this trial (Table 1 ) demonstrated no PrEP efficacy among transgender women, in an intent-to-treat analysis [49••] . Adherence among transgender women was remarkably low at 18%. None of the transgender women who had blood levels of TDF consistent with taking at least four pills a day seroconverted; and none of the transgender women who seroconverted had detectable levels of TDF in their blood.
Of note, iPrEx participants who were taking hormone therapy had lower levels of TDF detected than those who did not, suggesting that transgender women either prioritized hormone therapy over PrEP or that a drug-drug interaction may exist [49••] . While there is no evidence of drug-drug interactions -Pre-and post-test.
-Participant satisfaction was consistently high, as well as attendance. -Participants reported wanting more time to discuss session topics, appreciated opportunity for sisterhood and social interaction, expressed commitment to goals set during HOW. -Increase in HIV knowledge, condom use self-efficacy, and condom use (n. sig.). -Lower levels of depressive symptoms and higher levels of positive coping (sig.).
Collier et al. [70] Biomedical (N = 1)
iPrEx Trial: sub-analysis of Transwomen RCT of oral FTC/TDF PrEP versus placebo among men who have sex with men and transgender women, followed by an open-label extension.
People assigned male-sex-at-birth, regardless of current gender identity. N = 339 transgender women.
-RCT evaluation design -Among transgender women, 11 HIV infections in the active arm and 10 in placebo arm (intention-to-treat analysis). -Among active arm participants, drug was detected in none of the transgender women at the seroconversion visit, 18% (6/37) of seronegative transgender woman (p = 0.31), and 52% (58/111) of seronegative MSM (p < 0.0001). -Barriers to adherence among transgender women.
Deutsch et al. [49] Structural (n = 1)
Legal name change as a structural intervention
Transgender women of color recruited through no-cost legal clinic in New York, either currently enrolled in legal name change process or had completed in the last 9 months. N = 37 pre-name change and 28 post-name change.
-Cross-sectional group comparison approach.
-Post-name change group was significantly more likely to have a higher monthly income and stable housing than the prename change group. -No significant differences in general healthcare utilization, but significantly greater percentage of transgender women in the pre-name change group reported postponing medical care due to gender identity. -Significantly larger proportion of transgender women in the pre-name change group reported using non-prescribed hormones injected by friends and experiencing verbal harassment by family and friends compared to transgender women in the post-name change group.
Hill et al. [71] between TDF and estrogen-containing oral contraceptives medications [50] , there are tissue specific in vitro differences in TDF pharmacokinetics in the presence of estrogen [51] [52] [53] . Therefore, it is feasible that use of exogenous estradiol for medical gender affirmation may affect the pharmacokinetics of TDF in colon tissue-a critical site for PrEP efficacy among people who engage in receptive anal intercourse. We identified one ongoing study focused on assessing pharmacokinetics of TDF in colon tissue of transgender women on hormone therapy ( Table 2) . As of May 2017, more than 33 PrEP demonstration projects are underway that include transgender people, typically transgender women [54] . However, in these projects, transgender women are usually subsumed within studies tailored for MSM or cisgender female sex workers, and sample sizes are often insufficient for meaningful statistical inference. Only three of these demonstration projects are transgender-specific (Table 2) , and all take place in California. Collectively, these projects, funded by the California HIV/AIDS Research Program, aim to identify effective strategies for increasing PrEP uptake and adherence among transgender populations as well as to assess drug-drug interactions between hormone therapy and PrEP [55] . As of June 1, two NIH-funded transgender-specific PrEP-focused intervention studies are underway [56] . One of these studies, TransPrEP, seeks to pilot a social network-based PrEP adherence intervention for transgender women in Lima, Peru, using a combination of individual counseling, group workshops, social media-based network interactions, and practical support. The other study, TransLife in Chicago, focuses on social and structural determinants of health, providing a drop-in center where participants can access legal and employment services, transgender-affirming health education, and linkage to medical care as well as transcultural competency training for social service and medical providers.
Treatment as Prevention (TasP) is another powerful biomedical tool for HIV prevention. Rigorous studies have demonstrated lack of HIV transmission from people with HIV whose viral loads are below the level of detection [57, 58] . Studies across the USA are underway to determine effective strategies for specifically engaging transgender women of color in HIV care and treatment adherence. From 2012 to 2017, the Health Services and Resources Administration's (HRSA) Special Programs of National Significance (SPNS) funded nine demonstration projects under the Enhancing Engagement and Retention in Quality HIV Care for Transgender Women of Color Initiative [59, 60•] . Now nearing completion, most of the HRSA SPNS funded projects combine peer-led community outreach with a variety of other approaches (e.g., case management, small group sessions, motivational interviewing) to engage transgender women of color in the HIV care continuum. Four of the community sites partnered with local clinics to provide access to integrated gender-affirming and HIV-related health care. Several HRSA SPNS projects included behavioral interventions designed to improve ART adherence. For example, Just One of the Girls (JOG), a component of the Infinit-T intervention, aimed to improve linkage to and retention in HIV care using a five-module curriculum during a two-day retreat. The retreat focused on pride and self-esteem coupled with HIV knowledge and awareness of healthcare options. The Alexis Project also used a biobehavioral approach through their contingency management strategy designed to encourage retention in HIV care and reaching treatment milestones through increasing valuable incentives (e.g., gift cards), in conjunction with peer navigation.
Structural Interventions
Structural HIV interventions are less commonly studied than behavioral and biomedical interventions [61] . They can be complex to design and challenging to implement. They generally require more funding than behavioral interventions, may necessitate a change in widespread societal norms and significant political commitment, and are oftentimes politically controversial [62] . However, structural interventions may also have the greatest potential for population-level impact [34] . There are currently no outcome data available on HIVspecific structural interventions with transgender populations; however, several such interventions are now under study.
The Feminas Project in Lima, Peru is an ongoing study to assess the impact of concurrent access to hormone therapy and HIV prevention and treatment services for transgender women. Preliminary data suggest that participants feel more empowered to pursue HIV care in a context where their gender is affirmed [63, 64] . Through a pathway of gender affirmation, access to hormone therapy may also lead to decreased engagement in sexual risk behaviors and better mental health [36, 63] . Girlfriends Connect is another structural intervention underway. This study links high-risk transgender women who are returning to their communities after incarceration to case management-like services. During six planning sessions (preand post-release), transgender women receive one-on-one support and linkage to general health care, gender affirming medical care, and transitional needs like housing and employment. They also develop personal risk reduction plans, which are reassessed and revised depending on post-release experiences. The third identified structural intervention under study, the Brandy Martell Project (BMP) offers legal aid to participants facing legal barriers to seeking or adhering to HIV care and treatment, and it facilitates access to job training, mentorship, and other personal growth opportunities. Each of these structural interventions seeks to facilitate individual participant's access to gender affirmation, social resources, and health care, thereby addressing significant social drivers of HIV for transgender women. However, the individual-level approaches employed by the structural interventions currently under study do not affect legal and policy changes most likely to have a population-level impact [65] . https://hab.hrsa.gov/about-ryan-white-hivaidsprogram/spns-transgender-women-color
The Alexis Project Eighteen-month intervention that combines application of Contingency Management (CM) and Peer Health Navigation. Aims to improve linkage to and retention in HIV primary care, and achieve viral load suppression among HIV-infected transgender women of color. Participants can earn CM rewards for confirmed linkage to HIV primary care, retention in HIV care, and reaching HIV milestones.
HIV-positive transgender women of color residing in Los Angeles.
https://hab.hrsa.gov/about-ryan-white-hivaidsprogram/spns-transgender-women-color The TRIUMPH Collaborative Culturally relevant, community-led PrEP demonstration project. Aims to develop (1) an efficient PrEP delivery system within a network of clinics and community-based organizations through programming designed specifically to serve transgender communities and (2) a culturally relevant, adaptive intervention to increase PrEP uptake and support adherence among transgender communities.
Transgender people, with focus on transgender women of color, residing in San Francisco and Sacramento.
At least 40% of the sample will be persons of color and at least 20% Black. Existing data provide a road map for interventions that can be implemented now. Organizations can implement transgender-specific group-based interventions with skilled facilitators, preferably individuals of transgender experience. HIV prevention and care services should ensure genderaffirming policies and practices, and explore provision of parallel services valued by transgender persons (e.g., hormone therapy) [1] . In the US context, policy and advocacy are needed to maintain Affordable Care Act provisions mandating anti-discriminatory care and coverage, which are essential to HIV prevention in this population. In consultation with local communities, transgender-focused strategies to increase PrEP and ART adherence can be developed and tested, including providing accurate information about drug interactions with hormones used for medical affirmation. Such interventions can be refined as the results of ongoing studies become available.
While research on transgender health and HIV continues to accumulate [5] , knowledge is limited on HIV transmission and acquisition vulnerabilities among partners of transgender people, effective interventions for transgender men, and specific structural interventions to reduce HIV incidence in transgender populations. Our scoping review pointed to a number of gaps in the predominantly behavioral HIV prevention and care intervention research with transgender populations conducted to date. Specifically, these gaps include: (1) a significant dearth of research focused on transgender men and other transgender sub-populations (e.g., people with non-binary gender identities) who may experience unique HIV risk dynamics, (2) widespread inclusion of small samples of transgender women in intervention studies designed for MSM, and (3) limited research on structural, multi-level, and/or integrated intervention models with transgender populations. Given this HIV prevention landscape, future intervention research and implementation should prioritize the following:
(1) Ensure that all data collection (e.g., national censuses, demographic and health surveys, research enrollment tables) identifies and disaggregates data for transgender people and allows for selection of gender identity options beyond the male-female binary. (2) Tailor interventions for transgender people, including understudied sub-populations. (3) Design and evaluate innovative multi-level, biobehavioral, and/or integrated intervention models that address HIV in conjunction with gender affirmation. (4) Design and evaluate multi-level structural interventions that address HIV by prioritizing distal structural and social drivers of HIV risk. (5) Adapt and evaluate existing evidence-based HIV interventions (e.g., from the US CDC compendium of evidencebased interventions) for transgender populations. (6) Where transgender-specific research is not possible, ensure recruitment strategies, study design, and intervention components are trans-inclusive and powered to provide meaningful data for transgender people.
Using insights gained from existing data and being generated by ongoing research, it is feasible to significantly reduce the impact of HIV on transgender communities by preventing new infections and ensuring access to full engagement along the HIV care continuum.
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